Steminent Biotherapeutics Inc. (TPEX:7729)
Taiwan · Delayed Price · Currency is TWD 197.00
+3.00 (1.55%)
Sep 24, 2026, 2:59 PM CST
Steminent Biotherapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
15.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 941.00K | 305.00K | 47.96% |
| Dec 31, 2022 | 636.00K | -1.49M | -70.01% |
| Dec 31, 2021 | 2.12M | -49.35M | -95.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.19B |
| EirGenix | 1.21B |
| Ever Supreme Bio Technology | 1.08B |
| TaiMed Biologics | 619.49M |
| Medigen Vaccine Biologics | 573.85M |
| Oneness Biotech | 153.78M |
| ACRO Biomedical | 52.76M |
| Gongwin Biopharm Holdings | 42.22M |